Picture Kentro Design Is Key to Your Success Berlin 650x100px
Document › Details

Cytel Inc.. (9/26/23). "Press Release: Cytel Continues Expansion of Market Access and Medical Communication Capabilities with the Acquisition of Co.faktor". Waltham, MA.

Region Region Berlin
  Country Germany
Organisations Organisation Cytel Inc.
  Group Cytel (Group)
  Organisation 2 Co.faktor GmbH
  Group Cytel (Group)
Product Product  healthcare services
Index terms Index term Co.faktor–Cytel: investment, 202309 acquisition of Co.faktor GmbH by Cytel Inc
  Index term 2 Cytel–BioStrata: public relations, 202309 service existent by BioStrata
Persons Person Wasiak, Radoslaw (Radek) (Cytel 202309 General Manager Real World + Advanced Analytics)
  Person 2 Esser, Marc (Co.faktor 202309 Managing Director (CEO) + Founder)

Cytel Inc., provider of quantitative insights and health data analytics to leaders in the life sciences, has acquired the Berlin-based company co.faktor GmbH with its dedicated healthcare consultancy services co.value® (market access), co.medical® (medical communications), and co.patient® (patient relations) concentrations. As a result, Cytel’s services for biopharma commercialization will gain new and complementary specialist consultancy capabilities and localized expertise for successful market access in Germany, a first wave launch country. The acquisition marks another milestone in Cytel’s strategic growth in Europe, and follows the recent acquisition of stève consultants, specialists in market access, real-world evidence (RWE), and health economics and outcomes research (HEOR) in France. Cytel now boasts a 200-person-strong access consultancy team, making it one of the only providers that offers the full fleet of advisory services, from clinical trial and real-world data and evidence analytics to global market access and local in-country Health Technology Assessment (HTA) support.

Cytel is now primed to provide global drug sponsors and their affiliate teams with advanced analytical support across the lifecycle through commercialization. Achieving favorable market access in today’s global healthcare industry is challenging and requires deep knowledge of EU national regulations. Cytel has long excelled at using proven quantitative techniques to help pharmaceutical manufacturers successfully enter new markets. To continue supporting global and local clients on their road to commercial success, Cytel has invested heavily in specialized, national capabilities in key launch markets with the recent acquisitions of stève consultants in June 2023 and SDS Life Sciences in 2022. Cytel’s most recent acquisition of the co.faktor businesses continues this investment, augmenting and extending localized regulatory support through product launch and commercialization.

“The co.faktor team is recognized as a highly specialized biopharma services provider, with a broad spectrum of services including HTA, pricing, medical communication, patient relations, and strategic consultancy in Germany. It’s no surprise they’ve shaped the field there,” said Radek Wasiak, General Manager, Real-World & Advanced Analytics at Cytel. “We look forward to welcoming them to Cytel, where they will now be supported by the full depth and breadth of our unparalleled biometrics, RWE, HEOR, and market access advisory talent.”

“Cytel and co.faktor have clear synergies, particularly when it comes to Cytel’s data know-how and co.faktor’s understanding of Germany’s uniquely complex market access and HTA requirements,” said Dr. Marc Esser, CEO, co.faktor. “By combining our deep expertise in the German HTA process with Cytel’s unique capabilities, we will be able to help our clients survive the upcoming European Health Technology Assessment (EU-HTA), a key challenge for all stakeholders in the European pharma market.”

To learn more about Cytel’s access advisory capabilities, please visit:

For more information about co.faktor and its consultancy services, please visit:

About Cytel

Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution. For over thirty-five years, Cytel’s scientific rigor and operational excellence have enabled biotech and pharmaceutical companies to navigate uncertainty, prove value and make confident, evidence-based decisions. Its experts deliver industry-leading software, data-driven analytics, real-world evidence, and strategic consulting. Headquartered in Waltham, Massachusetts, Cytel has more than 1,900 resources across North America, Europe, and Asia. For more information about Cytel, please visit us at

About co.faktor

For more than 10 years, Berlin-based co.faktor GmbH has been providing specialized consulting services with its dedicated healthcare consultancy services co.value® (market access), co.medical® (medical communications), and co.patient® (patient relations) concentrations. By synergistically combining the expertise in these areas, co.faktor offers efficient launch support with consistent messaging to all relevant stakeholders. For more information about co.faktor, please visit

The names of co.faktor’s products and services referred to in this press release are trademarks or registered trademarks of co.faktor.


For more information:

Kimberley Sirk, Senior Director, Content & Communications
Cytel Inc.
+1 984-464-1375

Hans Hirsch, Business Development Consultant
co.faktor GmbH
+49 30 403619780

For media inquiries:
Jo Butler
+44 (0)1223 627120

Record changed: 2024-01-06


Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for Cytel (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top